Site map – MPN Research Foundation
Skip to content
Search for...
RESEARCH
Research Impact
MPN Challenge™
MPN Roundtable™
Patient-Focused Drug Development
2022 Thrive Initiative
MPN Interferon Initiative
Apply For Research Funding
PATIENTS & CAREGIVERS
MPN Clinical Trials
Patient & Caregiver Stories
Patient & Caregiver Resources
Living with an MPN
Find Support
UNDERSTANDING MPNS
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)
Myelofibrosis (MF)
30 Facts about MPNs
Glossary
SUPPORT US
Make a Donation
Other Ways to Give
Create Your Own Fundraiser
ABOUT MPNRF
Our Mission & History
Board of Directors
Our Team
Scientific Advisory Board
News & Articles
Newsletters
Our Partners
DONATE
JOIN COMMUNITY
SITE MAP
ABOUT US
LET THE FDA KNOW ABOUT YOUR EXPERIENCE LIVING WITH PV, ET OR MF!
JOANN MASON ATTENDS MPN ROUNDTABLE IN CHICAGO
MPN UPDATES FROM ASCO 2019
MPNRF’S EXECUTIVE DIRECTOR DISCUSSES THE INTERFERON INITIATIVE
NEW CLINICAL TRIALS AVAILABLE FOR MPN PATIENTS
MPNRF celebrates 1st annual Founder’s Day
SIERRA ONCOLOGY LAUNCHES THE MOMENTUM PHASE 3 CLINICAL TRIAL FOR PATIENTS WITH MYELOFIBROSIS
JANUARY NEW DONOR CHALLENGE
IDENTIFICATION OF TET2 AND CALR
Understanding MPNS
Myelofibrosis
Essential thrombocythemia (ET)
Polycythemia Vera (PV)
GLOSSARY
Our Mission and History
About MPNRF
Board of Directors
MPNRF Team
Scientific Advisory Board
Our Research Impact
Meet our MPN Community Partners
Living with an MPN
Financials
JUST DIAGNOSED
Find support
TREATMENTS
Blog
Patient’s Bill of Rights
MPN CLINICAL TRIALS
Patient & caregiver stories
NEWS
MPD Foundation President, Bob Rosen, attends 2004 ASH Conference in San Diego, California
LETTER FROM THE PRESIDENT
I5 WEEKS AFTER HEALTH COLLAPSE, COACH BACK IN BELOVED ROUTINE
MPD FOUNDATION FUNDS RESEARCH FOR INCURABLE BLOOD DISORDERS
UIC JOINS FORCES WITH HARVARD, MAYO CLINIC TO BATTLE BONE MARROW DISORDERS
MPD GENE MUTATION DISCOVERED!
AFTER DISCOVERING THE JAK2 MUTATION: NEXT STEPS IN DEVELOPING TARGETED TREATMENTS FOR PV, ET AND MF
BIKE RIDE FUND-RAISER IN MEMORY OF BELMONT CYCLIST
UIC RECEIVES $20 MILLION NCI GRANT TO RESEARCH BLOOD DISORDERS
NOVARTIS DRUG
GLEEVEC(R) APPROVED IN THE US FOR FIVE RARE LIFE-THREATENING DISORDERS WITH LIMITED TREATMENT OPTIONS
STUDY LINKS ESAS TO HIGHER LEUKEMIA RISK FOR SOME
DISCOVERY OF A NEW MUTATION IN JAK2V617F NEGATIVE MYELOFIBROSIS PATIENTS
UNIVERSITY OF UTAH TO INVESTIGATE BLOOD DISORDERS
RESEARCHERS ADVANCING BLOOD CANCER THERAPIES RECEIVE $42.75 MILLION IN GRANTS FROM THE LEUKEMIA & LYMPHOMA SOCIETY
EXELIXIS WINNING PHASE I RACE
NOVARTIS ENTERS INTO PARTNERSHIP WITH INCYTE
GENE MUTATION PREDICTS OUTCOME IN BLOOD DISORDER
EXELIXIS REPORTS DATA FROM ONGOING PHASE 1 STUDY OF XL019 TO TREAT MYELOFIBROSIS – UPDATE
TOP SCIENTISTS TO RECEIVE PRESTIGIOUS AWARDS FROM THE AMERICAN SOCIETY OF HEMATOLOGY
JAK2 INHIBITOR SHOWS POTENT ACTIVITY IN CELLS FROM MPD PATIENTS
TARGEGEN ANNOUNCES INITIATION OF CLINICAL TRIAL OF JAK2 INHIBITOR TG101348 IN MYELOPROLIFERATIVE DISEASE PATIENTS
CYTOPIA NOMINATES JAK2 CLINICAL CANDIDATE FOR MYELOPROLIFERATIVE DISORDERS
INCYTE REPORTS PROGRESS IN MULTIPLE CLINICAL PROGRAMS AND EXPANDS JAK INHIBITOR PROGRAM
UCSD, TARGEGEN TEAM-UP ON BLOOD DISEASE TREATMENT
REQUEST FOR PROPOSALS
CYTOPIA APPOINTS STUDY CHAIRMAN FOR JAK2 CLINICAL TRIAL
WATCH THE WEST PALM BEACH PATIENT SYMPOSIUM PRESENTATIONS
SEEKING PATIENTS FOR FAMILIAL MPN STUDY
CEMM IDENTIFIES INHERITED SUSCEPTIBILITY FOR A BLOOD MALIGNANCY
PATIENT STORIES
MPN WOMEN WARRIORS
RON
VIVIENNE
DR. DONALD
JULIE
DON
BECKY
SIMRAN
CORNELIU
JOY
MARY
DOUG
ALEX
KYLE
BRIDGET
JEAN
IGNACIO
JOAN
About MPNRF
Our Mission and History
Our Impact
Board
Staff
Meet Our Partners
Newsletter Sign-Up
Contact Us